LFCR SHAREHOLDER ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Lifecore Biomedical, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit!
NEW YORK CITY, NY / ACCESSWIRE / August 1, 2024 / Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, notifies investors that a class action lawsuit has been filed against Lifecore Biomedical, Inc. ("Lifecore" or "the Company") (NASDAQ:LFCR) and certain of its officers. Class Definition This lawsuit seeks to recover damages against Defendants for alleged violations of the federal securities laws on behalf of all persons and entities that purchased or otherwise acquired Lifecore securities between October 7, 2020, and March 19, 2024, inclusive (the "Class Period").
LFCR INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Lifecore Biomedical, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit!
NEW YORK CITY, NY / ACCESSWIRE / July 31, 2024 / Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, notifies investors that a class action lawsuit has been filed against Lifecore Biomedical, Inc. ("Lifecore" or "the Company") (NASDAQ:LFCR) and certain of its officers. Class Definition This lawsuit seeks to recover damages against Defendants for alleged violations of the federal securities laws on behalf of all persons and entities that purchased or otherwise acquired Lifecore securities between October 7, 2020, and March 19, 2024, inclusive (the "Class Period").
LFCR INVESTOR NOTICE: Lifecore Biomedical, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit
SAN DIEGO, CA / ACCESSWIRE / July 31, 2024 / The law firm of Robbins Geller Rudman & Dowd LLP announces that purchasers or acquirers of Lifecore Biomedical, Inc. (NASDAQ:LFCR) securities between October 7, 2020 and March 19, 2024, both dates inclusive (the "Class Period"), have until September 27, 2024 to seek appointment as lead plaintiff of the Lifecore Biomedical class action lawsuit. Captioned Carew v.
Lifecore Biomedical Inc Is Being Investigated By The Schall Law Firm Which Urges Investors With Losses To Start A Conversation
LOS ANGELES, CA / ACCESSWIRE / July 31, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Lifecore Biomedical, Inc. ("Lifecore" or "the Company") (NASDAQ:LFCR) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.
SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Lifecore Biomedical, Inc. of Class Action Lawsuit and Upcoming Deadlines - LFCR
NEW YORK, NY / ACCESSWIRE / July 30, 2024 / Pomerantz LLP announces that a class action lawsuit has been filed against Lifecore Biomedical, Inc. ("Lifecore" or the "Company") (NASDAQ:LFCR) and certain officers. The class action, filed in the United States District Court for the District of Minnesota, and docketed under 24-cv-03028, is on behalf of a class consisting of all persons and entities other than Defendants that purchased or otherwise acquired Lifecore securities between October 7, 2020, and March 19, 2024, both dates inclusive (the "Class Period"), seeking to recover damages caused by Defendants' violations of the federal securities laws and to pursue remedies under Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 (the "Exchange Act") and Rule 10b-5 promulgated thereunder, against the Company and certain of its top officials.
Lifecore Biomedical Inc Is Under Scrutiny By The Schall Law Firm Which Encourages Investors With Losses To Initiate Dialogue
LOS ANGELES, CA / ACCESSWIRE / July 30, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Lifecore Biomedical, Inc. ("Lifecore" or "the Company") (NASDAQ:LFCR) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.
Lifecore Biomedical Inc Is Under Scrutiny By The Schall Law Firm Which Encourages Investors With Losses To Initiate Dialogue
LOS ANGELES, CA / ACCESSWIRE / July 29, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Lifecore Biomedical, Inc. ("Lifecore" or "the Company") (NASDAQ:LFCR) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.
Lifecore Biomedical Inc Under Scrutiny By The Schall Law Firm Encourages Investors With Losses To Begin Dialogue
LOS ANGELES, CA / ACCESSWIRE / July 26, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Lifecore Biomedical, Inc. ("Lifecore" or "the Company") (NASDAQ:LFCR) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.
Lifecore Biomedical Inc Under Scrutiny By The Schall Law Firm Encourages Investors With Losses To Begin Dialogue
LOS ANGELES, CA / ACCESSWIRE / July 25, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Lifecore Biomedical, Inc. ("Lifecore" or "the Company") (NASDAQ:LFCR) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.
Lifecore Biomedical Inc Under Scrutiny By The Schall Law Firm Encourages Investors With Losses To Begin Dialogue
LOS ANGELES, CA / ACCESSWIRE / July 24, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Lifecore Biomedical, Inc. ("Lifecore" or "the Company") (NASDAQ:LFCR) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.
Lifecore Biomedical Inc Under Scrutiny By The Schall Law Firm Encourages Investors With Losses To Begin Dialogue
LOS ANGELES, CA / ACCESSWIRE / July 23, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Lifecore Biomedical, Inc. ("Lifecore" or "the Company") (NASDAQ:LFCR) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.
Lifecore Biomedical Inc Under Scrutiny By The Schall Law Firm Encourages Investors With Losses To Begin Dialogue
LOS ANGELES, CA / ACCESSWIRE / July 22, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Lifecore Biomedical, Inc. ("Lifecore" or "the Company") (NASDAQ:LFCR) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.
